Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicentre, Epidemiological Study Assessing the Impact of Childhood Vaccination with PCV13 and PCV7 on Distribution of Streptococcus Pneumonia Serotypes (PCV13 and PCV7) in Immunocompetent Adults Hospitalized with Community Acquired Pneumonia (CAP)

Next Previous
Trial Profile

A Prospective, Multicentre, Epidemiological Study Assessing the Impact of Childhood Vaccination with PCV13 and PCV7 on Distribution of Streptococcus Pneumonia Serotypes (PCV13 and PCV7) in Immunocompetent Adults Hospitalized with Community Acquired Pneumonia (CAP)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Community-acquired pneumonia
  • Focus Therapeutic Use
  • Acronyms CAPA
  • Sponsors Pfizer

    • Most Recent Events

    • 14 Apr 2021 Results published in the Clinical Infectious Diseases
    • 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases.
    • 24 Apr 2018 Results of a study investigating specific serotypes causing pneumococcal CAP presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top